Kopran (KOPRAN)₹259.76−1.31%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Kopran reported sales of ₹155 Cr, up 13.9% from Jun 2025, and net profit of ₹6.69 Cr, down 10.0% year on year. For the year to Mar 2026, sales were ₹683 Cr and net profit ₹25.94 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 153 | 160 | 187 | 140 | 152 | 167 | 173 | 136 | 118 | 195 | 235 | 155 |
| Expenses | 130 | 136 | 165 | 122 | 137 | 147 | 156 | 121 | 123 | 177 | 202 | 139 |
| Operating Profit | 22.82 | 23.59 | 21.70 | 18.15 | 14.74 | 19.84 | 17.07 | 14.12 | −5.27 | 17.75 | 32.93 | 15.80 |
| OPM % | 15.0% | 14.9% | 11.7% | 13.1% | 9.8% | 12.0% | 10.0% | 10.5% | −4.4% | 9.2% | 14.2% | 10.3% |
| Other Income | 0.14 | 2.44 | 9.68 | 2.64 | 1.01 | 0.18 | 3.27 | 2.57 | 0.04 | 0.08 | 0.10 | 2.06 |
| Interest | 1.93 | 2.23 | 2.58 | 2.17 | 2.22 | 2.15 | 2.76 | 2.53 | 2.08 | 2.66 | 3.16 | 3.27 |
| Depreciation | 2.76 | 3.26 | 3.58 | 3.86 | 3.84 | 3.99 | 3.86 | 4.25 | 4.27 | 4.41 | 4.51 | 5.76 |
| Profit before tax | 18.22 | 20.48 | 25.15 | 14.72 | 9.63 | 13.84 | 13.69 | 9.87 | −11.60 | 10.72 | 25.28 | 8.80 |
| Tax % | 24.5% | 23.0% | 26.0% | 24.7% | 23.4% | 24.9% | 29.4% | 24.6% | −14.7% | 13.0% | 25.6% | 23.8% |
| Net Profit | 13.74 | 15.74 | 18.56 | 11.07 | 7.36 | 10.38 | 9.65 | 7.43 | −9.89 | 9.31 | 18.83 | 6.69 |
| EPS (Rs) | 2.87 | 3.29 | 3.87 | 2.31 | 1.54 | 2.17 | 2.02 | 1.55 | −2.07 | 1.95 | 3.92 | 1.40 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 297 | 311 | 314 | 359 | 361 | 493 | 480 | 553 | 617 | 632 | 683 | 702 |
| Expenses | 267 | 275 | 284 | 313 | 314 | 411 | 391 | 500 | 541 | 558 | 621 | 641 |
| Operating Profit | 29.98 | 35.99 | 31.01 | 45.95 | 46.98 | 81.94 | 86.95 | 52.03 | 74.01 | 72.93 | 61.98 | 61.21 |
| OPM % | 10.0% | 12.1% | 10.0% | 13.1% | 13.1% | 17.0% | 18.0% | 9.1% | 12.1% | 12.0% | 9.1% | 8.7% |
| Other Income | 1.01 | 11.02 | 9.01 | 3.01 | 0.00 | 18.03 | 11.01 | 3.01 | 15.01 | 4.01 | 0.00 | 2.28 |
| Interest | 12.98 | 13.99 | 8.99 | 8.98 | 8.98 | 5.99 | 4.99 | 5.99 | 8.98 | 8.99 | 9.98 | 11.17 |
| Depreciation | 7.98 | 7.98 | 8.97 | 8.98 | 9.98 | 9.97 | 10.97 | 12.96 | 12.97 | 15.97 | 16.95 | 18.95 |
| Profit before tax | 10.97 | 24.97 | 22.96 | 31.94 | 27.95 | 82.84 | 81.83 | 35.95 | 67.92 | 51.94 | 33.92 | 33.20 |
| Tax % | 0.0% | 20.0% | 10.0% | 24.0% | 26.0% | 26.0% | 25.0% | 24.0% | 25.0% | 26.0% | 25.0% | — |
| Exceptional items | −1.19 | 0.00 | −0.15 | −0.05 | −0.50 | −0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 10.98 | 19.97 | 19.94 | 23.96 | 20.94 | 61.87 | 60.86 | 26.91 | 50.85 | 38.88 | 25.94 | 24.94 |
| EPS (Rs) | 2.49 | 4.61 | 4.75 | 5.56 | 4.87 | 14.27 | 12.69 | 5.66 | 10.60 | 8.01 | 5.34 | 5.20 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 21.1% | 24.1% | 53.1% | 28.1% | 38.1% | 56.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41.13 | 43.12 | 43.12 | 43.15 | 43.13 | 43.14 | 43.13 | 48.17 | 48.12 | 48.19 | 48.12 | 48.17 |
| Reserves | 49.13 | 57.15 | 81.20 | 101 | 125 | 146 | 202 | 379 | 392 | 444 | 471 | 483 |
| Borrowings | 85.86 | 79.89 | 94.91 | 88.92 | 96.94 | 87.96 | 65.93 | 74.86 | 74.97 | 98.94 | 148 | 153 |
| Other Liabilities | 99.18 | 84.10 | 77.97 | 81.97 | 84.88 | 91.84 | 128 | 110 | 134 | 152 | 178 | 224 |
| Total Liabilities | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 612 | 651 | 743 | 845 | 909 |
| Fixed Assets | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 208 | 346 |
| CWIP | 1.01 | 3.01 | 5.99 | 9.99 | 24.02 | 29.99 | 43.02 | 35.99 | 70.03 | 96.99 | 113 | 24.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 172 | 160 | 187 | 202 | 214 | 230 | 284 | 426 | 416 | 466 | 523 | 538 |
| Inventories | 44.90 | 58.81 | 60.84 | 70.78 | 72.78 | 87.68 | 99.67 | 150 | 131 | 138 | 169 | 163 |
| Trade receivables | 81.31 | 57.25 | 73.28 | 65.25 | 87.34 | 93.33 | 120 | 127 | 164 | 213 | 216 | 264 |
| Cash & equivalents | 4.01 | 5.01 | 7.01 | 6.01 | 4.01 | 5.01 | 7.01 | 57.10 | 13.02 | 14.01 | 26.03 | 7.01 |
| Total Assets | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 612 | 651 | 743 | 845 | 909 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 46.17 | 29.12 | 16.07 | 26.10 | 25.10 | 31.13 | 60.20 | −33.11 | 34.14 | 43.15 | 42.20 | 67.24 |
| Cash from investing activity | −9.97 | −8.98 | −17.95 | −10.96 | −24.94 | −12.96 | −24.91 | −83.81 | −12.97 | −43.88 | −55.82 | −64.85 |
| Cash from financing activity | −37.12 | −19.05 | 2.01 | −15.04 | −1.01 | −18.06 | −35.13 | 123 | −20.08 | 1.01 | 26.07 | −21.07 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.01 | 2.01 | 1.01 | 11.02 | −19.03 |
| Capex | 10.96 | 10.95 | 15.95 | 11.97 | 30.90 | 13.95 | 16.93 | 42.82 | 60.76 | 56.79 | 58.75 | 66.75 |
| Free cash flow | 34.99 | 17.99 | 0.00 | 13.98 | −5.99 | 16.97 | 42.99 | −75.98 | −26.98 | −12.99 | −16.99 | 0.00 |
| CFO / OP % | 147.1% | 95.1% | 47.1% | 94.1% | 63.1% | 82.0% | 93.0% | −16.9% | 90.0% | 77.0% | 76.1% | 117.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 90 | 69 | 85 | 74 | 87 | 93 | 88 | 96 | 107 | 125 | 124 | 140 |
| Inventory days | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 | 137 |
| Days payable | 118 | 114 | 94 | 117 | 89 | 94 | 103 | 83 | 88 | 102 | 107 | 130 |
| Cash conversion cycle | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 | 146 |
| Working capital days | 9 | 34 | 43 | 60 | 70 | 79 | 81 | 158 | 139 | 131 | 113 | 91 |
| ROCE % | 14.1% | 14.1% | 19.1% | 14.1% | 16.1% | 14.1% | 30.1% | 21.1% | 8.0% | 14.0% | 10.1% | 7.0% |
For the Jun 2026 quarter, Kopran reported sales of ₹155 Cr, up 13.9% year on year and net profit of ₹6.69 Cr, down 10.0% year on year. The operating margin was 10.3%.
Kopran's sales for the year to Mar 2026 were ₹683 Cr; over the last twelve months they were ₹702 Cr.
Net profit for the year to Mar 2026 was ₹25.94 Cr, and ₹24.94 Cr over the last twelve months. Earnings per share over the same trailing period were ₹5.20.
Kopran reported borrowings of ₹153 Cr at Mar 2026, against cash and equivalents of ₹7.01 Cr.
Cash from operations was ₹67.24 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0 Cr.